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Abstract. The levels of expression of the ras family genes, 
in 14 tumour specimens from squamous cell carcinomas of 
the larynx were analysed by reverse transcription-polymerase 
chain reaction. The Η-ras was overexpressed in 12 (86%) 
samples, K-ras in 11 (78%) and N-ras in 8 (57%) samples. 
All tumours exhibited overexpression of at least one member 
of the ras family. In addition, each member of the ras family 
was activated independently from the rest of the ras family 
genes. The incidence of amplification in the ras family genes 
was also analysed by differential PCR: K-ras was found 
amplified in 14% (2/14), N-ras in 7% (1/14) and Η-ras in 
none of the samples tested. Amplification data exhibited no 
association with the expressional levels of the ras genes. 
Furthermore, we investigated the incidence of codon 12 point 
mutations in the ras family genes but no mutation was found. 
The present study indicates that overexpression of the ras 
family genes is important for the development of the disease 
and it is not associated with the amplification status of the 
genes. In addition, the differential regulation among the 
members of the ras family might play a role in the development 
of laryngeal tumours. 
Introduction 
Ras family genes (H-, K- and N-ras) encode for a 21 kD 
(p21 r a t) protein which possesses GTPase activity and 
participates in a signal transduction pathway (1). Activated 
ras oncogenes have been detected frequently in human 
cancers and this alteration has been associated with the 
development of the disease (2). Mutations at codons 12, 13 
and 61 are considered the main activating mechanism for the 
ras family genes. However, aberrant expression of the ras 
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genes, has been recognised in several human cancers and has 
been associated with the development of the neoplasia (3), 
since overexpression of even normal ras alleles confer a 
transforming potential (4). 
Most of the investigations concerning ras expression in 
human tumour tissues have been performed by immuno­
assays, with antibodies that failed to distinguish the products 
of the three ras family genes. However, overexpression of 
p21"" has been recognised as a common feature of several 
human tumours, including breast (5), colorectal (6) and 
squamous cell carcinomas of the head and neck (7). 
The levels of expression of the individual ras genes has 
been assessed, but these analyses related mainly to the 
expression of the H-ras (8,9) and sometimes to the K-ras (9) 
as well. However, differential expression of the ras genes in 
human tumours, is probably important in tumorigenesis, 
although the particular properties of p21"" derived by each 
ras family gene are unknown. A different role for each of the 
ras genes has been postulated by Leon et al (10), who found 
that the ras family genes are differentially expressed in the 
normal tissues of the mouse. 
Amplification of the ras genes is a detectable disorder 
which most frequently is accompanied by a mutation in the 
amplified allele (11). The amplification of specific genes, 
results in a gene dosage effect which is frequently reflected in 
the levels of expression of the particular allele which is 
amplified. 
Differential expression analysis of the ras genes in human 
tumour tissues has not been performed, as yet. In the present 
study we investigated the levels of expression of the ras 
family genes in squamous cell carcinomas of the larynx. 
Furthermore, we investigated whether the overexpression of 
the ras family genes was caused by specific genetic 
aberrations that result in the amplification of these genes. In 
addition we analysed the incidence of codon 12 point 
mutations for the ras family genes. This site has the highest 
rate of activation of the ras family genes in human tumours (3). 
Materials and methods 
Specimens and RNA extraction. 14 fresh tumour specimens 
from squamous cell carcinomas of the larynx and two 
adjacent normal tissues were obtained from the Hippocration 
General Hospital, Department of Otorhinolaryngology, 
Athens. The specimens, were stored immediately after the 
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Table I. Primers and PCR products for the detection of codon 12 point mutations, expression and amplification of H-ras, 
K-ras and N-ras genes." 
gene sense primer antisense primer PCR (bp) product use 
H-ras 
H-ras 
K-ras 
K-ras 
N-ras 
N-ras 
N-ras 
ß-actin 
GAGACCCTGTAG 
GAGGACCC-3 
5-
GACGGAATATAA 
GCTGGTGG-3 
5-
ACTGAATATAAAC 
TTGTGGTAGTTG 
GACCT-3 
5-
ACTGAATATAAAC 
TTGTGGTAGTTG 
GACCT-3 
5-
AACTGGTGGTGG 
TTGGACCA-3 
GACATACTGGAT 
ACAGCTGGC-3 
5-
AATCCAGCTAATC 
CAGAACC-3 
5-
GTGGGGCGCCCA 
GGCACCA-3 
GGGTGCTGAGAC 
GAGGGACT-3 
5-
AGGCACGTCTCC 
CCATCAAT-3 
5-
TCAAAGAATGGT 
CCTGGACC-3 
5-
CAAATCACATTTA 
TTTCCTACCAGGA 
CCAT-3 
5-
ATATTCATCTACA 
AAGTGGTCCTGG 
A-3 
5-
CCTGTCCTCATGT 
ATTGGTC-3 
5-
TGGTCTCTCATGG 
CACTGTA-3 
5-
CTCCTTAATGTCA 
CGCACGATTTC-3 
312 
151 
157 
357 
83 
65 
150 
548 
a, m 
a, m 
m 
"Primers for the amplification of interferon-γ gene are described in ref. 12. a, amplification; m, mutation; e, expression 
dissection at -70°C for RNA extraction. Total RNA was 
extracted using TRIzol Reagent (Gibco BRL), following the 
manufacturer's instructions. 
Reverse transcription PCR and RNA quantitation. 200 ng of 
total RNA were reverse transcribed in a 50 μΐ reaction (10 mM 
Tris HCl; pH 8.3, 50 mM KCl, 1 mM MnCl2, 200 μΜ 
dNTPs, 200 ng antisense primer and 2.5 U Tth polymerase) 
for 15 min at 70°C. PCR amplification of cDNA was 
performed by adding 50 μΐ of buffer containing 75 mM Tris-
HC1 pH 9.0, 20 mM (NH 4) 2S0 4, 1.5 mM MgCl2, 0.01% 
Tween-20, 0.75 mM EGTA and 200 ng sense primer. The 
oligonucleotide primers used and the subsequent PCR 
products are listed in Table I. 
The PCR programs consisted of 1-min steps at 95°C, 
60°C and 72°C for 28 cycles. Preliminary experiments had 
revealed the conditions in which the amplification reaction 
remained in the exponential phase (data not shown) and thus 
the results could be used for quantitation of the template. 10 μΐ 
of the PCR product was electrophoresed through a 2% 
agarose gel and the intensity of the bands was analysed by a 
UVP image analysis system. 
Differential PCR analysis. The co-amplification (12) of the 
target gene (H-ras, K-ras and N-ras) and the reference gene 
interferon-γ was performed in a 50 μΐ reaction volume 
containing 300 ng of genomic DNA as a template and 500 μΜ 
dNTPs, 30 pM of each forward and reverse primer (Table I). 
0.5 U of Tag DNA polymerase and 5 μΐ of 10X buffer (670 mM 
Tris.HCl, pH 8.5; 166 mM ammonium sulphate; 67 mM 
magnesium chloride; 1.7 mg/ml BSA; 100 μΜ ß-mercapto-
ethanol and 1% (w/v) Triton X-100). 20 μΐ of the PCR 
product was electrophoresed through a 2% agarose gel. 
Detection of ras mutations at codon 12 by restriction 
fragment length polymorphism (RFLP). PCR amplification of. 
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Table II. Amplification and expression of the ras family genes in squamous cell carcinomas of the larynx. 
Patient number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
H-ras 
expression 
2.4 
1.8 
2.2 
2.3 
1.5 
2.0 
2.5 
2.4 
2.3 
1.3 
2.3 
1.5 
1.3 
1.5 
ampi ification 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
expression 
2.6 
1.1 
1.5 
1.9 
1.9 
1.6 
2.2 
2.3 
1.6 
1.8 
1.5 
1.5 
1.1 
1.2 
Gene 
K-ras 
ampli ification 
+ 
-
-
-
+ 
-
-
-
-
-
-
-
-
-
N-
expression 
2.7 
1.8 
2.8 
1.7 
1.1 
0.8 
2.0 
1.0 
0.7 
1.2 
1.7 
1.7 
2.4 
1.1 
ras 
amplification 
-
-
-
-
-
-
+ 
-
-
-
-
-
-
-
the ras genes surrounding codon 12 was performed as 
described above. 30 μΐ of the PCR product was digested 
overnight with 20 U of the restriction endonucleases M spi 
(Η-ras) and BstNl (K-ras and N-ras) in conditions 
recommended by the suppliers, electrophoresed in a 2% 
agarose gel and stained with ethidium bromide. 
Results 
Expression of the ras family genes. 14 tumour specimens 
from patients with squamous cell carcinomas of the larynx 
were analysed for the levels of expression of Η-ras, K-ras 
and N-ras proto-oncogenes. The expressional levels were 
interpreted as the ratio of the expression in each tumour 
specimen versus the average expressional levels of two 
adjacent normal laryngeal tissues of squamous origin. In 
addition, prior to the interpretation of the ras gene 
expression, amplification of ß-actin mRNA was performed in 
order to normalise the quality and the quantity of RNAs. The 
summary of our results is presented in Table II. RNA levels 
higher than 1.5 fold versus the levels of the control normal 
tissues were considered an overexpression. Η-ras exhibited 
overexpression in 12 (86%), K-ras in 11 (78%) and N-ras in 8 
(57%) samples. All samples tested exhibited overexpression 
of at least one member of the ras family, indicating that the 
overproduction of the p21"" is necessary for the development 
of laryngeal tumours. No association has been found between 
the expressional levels of the ras family genes and the 
clinicopathological parameters of the patients (i.e. nodes at 
pathology, histological differentiation and stage). 
Amplification of the ras family genes. As interpreted by the 
differential PCR analysis in which each one of the ras family 
genes where co-amplified with the interferon-γ gene, the 
incidence of amplification was very low. Our analysis 
revealed that only two among 14 (14%) samples harboured 
an amplified K-ras allele and only one among 14 (7%) 
samples was positive for N-ras amplification (Table II, Fig. 3). 
Amplification of the Η-ras proto-oncogene was not detected 
in any of the samples tested. In addition, amplification of the 
ras family genes was not associated with the expressional 
levels of these genes, confirming the suggestion of Sheng et 
al (13) in an analysis of a series of head and neck tumours for 
Η-ras expression and amplification. No association has been 
found between amplification and the clinicopathological 
parameters of the patients (Table III). 
Mutations at codon 12 of Η-ras, K-ras and N-ras genes. A 
combined PCR-RFLP assay was employed for the detection 
of codon 12 mutations of the ras family genes. The analysis 
failed to detect the presence of any mutations at codon 12 ras 
alleles in the laryngeal tumours tested. This is in agreement 
with previous investigations that indicated low levels of 
mutational activation of the ras family genes in head and 
neck tumours in the Western world. 
Discussion 
In the present study we analysed the levels of expression and 
the incidence of amplification and codon 12 point mutations 
of the ras family genes in 14 specimens from patients with 
squamous cell carcinomas of the larynx. We employed for 
the ras expression analysis a reverse transcription-
polymerase chain reaction (RT-PCR) assay (14) for the 
detection of the H-, K- and N-ras mRNA levels. Two 
specimens from adjacent normal tissue were used as control 
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Table III. Clinicopathological parameters of 14 patients with 
squamous cell carcinomas of the larynx. 
1 2 3 4 5 6 7 8 9 N 1 N 2 
Patient 
number 
Stage Histological 
differentiation 
Nodes at 
pathology 
I 
2 
3 
4 
5 
6 
7 
8 
9 
IO 
ll 
12 
13 
14 
I 
III 
III 
III 
III 
I 
II 
II 
I 
II 
I 
II 
II 
III 
M 
-
M 
Ρ 
Ρ 
Ρ 
Μ 
Μ 
Ρ 
Ρ 
Ρ 
Μ 
Μ 
W 
W, well differentiated; Μ, moderately differentiated; Ρ, poorly 
differentiated 
in order to evaluate the background levels of expression of 
the ras family genes in the normal mucosa. The quantity and 
the quality of RNA samples, was normalised after 
amplification of ß-actin mRNA. The mRNA levels for each 
member of the ras family genes were expressed as the ratio 
of the intensity of the bands in the tumour tissues versus the 
average corresponding levels of the normal tissues (Fig. 1). 
Differential PCR was employed for the detection of 
amplified ras alleles. Co-amplification of the interferon-γ 
Η-res 
Κ-res 
Ν-ras 
β-actin 
Figure 1. Representative examples of RT-PCR applied to H-, K- and N-ras, 
in 9 tumour specimens of the larynx and two adjacent normal tissues. 
Amplification of ß-actin was performed in order to normalise the quality and 
the quantity of RNAs. The intensity of the bands, was analysed with a UVP 
image analysis system. 
gene served as internal control in this assay. The detection of 
mutations at codon 12 ras gene alleles was performed by a 
sensitive RFLP assay. 
The levels of Η-ras mRNA overexpression, ranged from 
1.4 to 2.6, for K-ras from 1.1 to 2.5 and for N-ras from 0.9 to 
2.6. We arbitrarily considered as overexpression, levels 
higher than 1.5 fold, versus the expressional levels in the 
control normal tissues. Η-ras exhibited overexpression in 12 
(86%), K-ras in 11 (78%) and N-ras in 8 (57%) samples. It is 
of specific interest, that all samples tested, exhibited 
overexpression of at least one member of the ras family, 
indicating that overproduction of p21ras, regardless of which 
gene is responsible for the overexpression, is required for the 
development of a malignant potential (Fig. 2). 
In order to investigate possible factors that may result in 
the overexpression of the ras family genes in tumour tissues. 
| H-ras [ ] K-ras |j N-ras 
10 11 12 13 14 
Figure 2. Relative expression of each ras family gene, in 14 squamous cell carcinomas of the larynx. The RNA levels for each gene, are expressed as the 
ratios between the intensity of the bands in the tumour tissues, versus the average intensity of the bands in the normal tissues. 
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Figure 3. a, Analysis of the K-ras gene for amplification. The K-ras (157 bp) 
and the interferon-γ (85 bp) gene products are indicated. Lanes 1,2,4 and 5 
correspond to negative samples and lanes 3 and 6 to samples positive for K-ras 
amplification, b, Application of the differential PCR to the N-ras gene. Lanes 
1, 3, 4 and 5 exhibit no evidence of N-ras amplification while lane 2 
corresponds to a sample with amplification of the N-ras gene. 85 bp band 
corresponds to the interferon-γ gene and 65 bp band corresponds to the N-ras 
gene. 
we assessed the incidence of amplification of these genes, by 
differential PCR. Differential PCR analysis revealed that 
only two among 14 (14%) samples harboured an amplified 
K-ras allele and only one among 14 (7%) samples was 
positive for N-ras amplification. Moreover, amplification of 
the Η-ras proto-oncogene was not detected in any of the 
samples tested. Although amplification of the ras genes is a 
rare event in laryngeal tumours, overexpression of these 
genes is frequent and it is not associated with the presence of 
amplified ras alleles. It seems that a gene dosage effect plays 
a minor role for the development of laryngeal tumours, at 
least as regards the ras family genes. Duesberg and co­
workers (15-17) postulated that mutations in the ras family 
genes were overlooked and overexpression of the normal 
alleles may be more important for the development of the 
disease. They suggested that mutations within the promoters 
of these genes or imbalance of chromosomes (resulting in the 
amplification) may provide further evidence to the 
understanding of oncogenesis. Although the present study 
failed to detect amplified ras alleles, the lack of ras 
mutations in addition to the overexpression of the normal 
alleles of the ras family, supports the forementioned hypothesis. 
The present study provides evidence that all three ras 
family genes are overexpressed in laryngeal tumours. 
Scambia et al (18) reported that p21 ",s levels in laryngeal 
tumours were elevated in almost all samples tested. The 
present investigation indicates that overproduction of p21"" 
is not due to the activation of only one member of the ras 
family, but all three ras family genes may be activated, in all 
combinations. 
The incidence of mutations in ras family genes in head 
and neck cancer is low in the Western world (19). This was 
confirmed by the present study since no mutations were 
found in the 14 samples from laryngeal tumours studied. 
However, overexpression of the ras genes possibly plays an 
important role in the development of the disease. It is now 
well established that apart from the qualitative changes (i.e. 
mutations), quantitative alterations in the expression of 
oncogenes, plays a critical role in carcinogenesis (20). In 
vitro experiments have shown that among transfected cells 
with similar copy numbers of exogenous proto-oncogenes of 
the ras family, only those that express high levels of ras 
mRNA are morphologically transformed (21). 
N-ras showed the lowest incidence (8/14; 57%) of 
overexpression, which may be due to the lower incidence of 
mutational activation for the N-ras in human tumours, among 
the ras family genes. This finding may indicate that N-ras 
possesses a weaker tumorigenic potential, as compared to 
Η-ras and K-ras, and thus, aberrations of this gene confer 
less to the malignant transformation. 
An additional point of the present analysis is that 
although some tumours exhibited overexpression of all ras 
family genes (Fig. 2; patients 1, 4, 14), some specimens 
exhibited activation of different ras gene(s), in all possible 
combinations (i.e. patients 2, 3, 9, 10, 11, 13). We could thus 
postulate the existence of multiple different genetic events 
(or factors) that result in the differential activation of the ras 
family genes. The overexpression of each of these factors, in 
combination with the different affinity this factor possesses 
with the regulatory regions for each of the ras genes, might 
be responsible for the differential activation they exhibit in 
the tumours. This is noteworthy because ras genes are 
considered housekeeping genes and inducible regulatory 
elements have not been recognised, as yet, in the promoter 
regions of these genes. The factors responsible for the 
differential regulation of ras family genes remain obscure. 
However, since ras family genes may behave independently 
in the tumours, we could postulate that these genes may be 
regulated differentially. Genetic events such as instability of 
the repetitive elements of at least Η-ras, have been postulated 
to play a role in the regulation of the gene (8,22). Furthermore, 
mutations within the regulatory regions of the ras family 
genes may be responsible for their altered expression, which 
is important for tumorigenesis. It has already been proved 
that the presence of retroviral promoters is important for the 
transformation properties of the ras family genes, indicating 
the generation of heterologous promoters (21,23). 
Apart from the contribution to the understanding of the 
basic mechanism of the disease, the studies on the expression 
of the ras family genes in human tumours, may prove to be 
useful in the development of therapeutic strategies. Several 
anti-cancer compounds have been developed (i.e. inhibitors 
to the farnesylation of p21™\ anti-sense oligonucleotides, 
etc.) that target directly the ras genes or their product p21"" 
(24). Assessment of the expressional levels of the ras family 
genes in each tumour may provide useful information as 
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regards the selection of these compounds and their potential 
role in the inhibition of the cancer cells of a specific type. 
This is the first study to our knowledge, that reports on 
the levels of expression of the ras family genes in human 
laryngeal tumours. We provided evidence that all three ras 
genes are transcriptionally activated in laryngeal tumours, 
indicating that overproduction of p21™ is required in the 
multistage process of the disease. In addition, we found 
differential activation of the ras genes in the tumours tested, 
and stated the hypothesis that the activation is the result of 
multiple genetic events. Since the incidence of amplification 
is very low as compared to that of overexpression, alternative 
mechanism that result in the transciptional activation of the 
ras family genes should be cons idered . This inc ludes 
mutations within the promoters of the ras family genes, as 
already proposed by Duesberg and co-workers (15-17). 
More in-depth studies are required, involving a wide 
range of tumours and a large number of samples, in order to 
clarify the precise role of the expressional aberrations of the 
ras genes in carcinogenesis. In addition the detection of hot 
spots for mutations within the non-coding regions of the ras 
family genes may play an important role for the regulation 
(and disregulation) of these genes and may provide clues for 
their role in the development of the disease. The role of 
activation of each individual ras gene in the development of 
the neoplasia also remains to be established. 
References 
1. Barbacid M: Ras genes. Annu Rev Biochem 56: 779-827, 1987. 
2. Bos JL: Ras oncogenes in human cancer (Review). Cancer Res 
49: 4682-4689, 1989. 
3. Field JK and Spandidos DA: The role of ras and myc onco­
genes in human solid tumors and their relevance in diagnosis 
and prognosis. Anticancer Res 10: 1-22, 1990. 
4. Spandidos DA and Wilkie NM: Malignant transformation of 
early passage rodent cells by a single mutated human oncogene. 
Nature 310: 469-475, 1984. 
5. Spandidos DA, Karaiossifidi H, Malliri A, Linardopoulos S, 
Vassilaros S, Tsikkinis A and Field JK: Expression of ras, Rbl 
and p53 proteins in human breast cancer. Anticancer Res 12: 
81-90, 1992. 
6. Spandidos DA and Kerr I: Elevated expression of the human ras 
oncogene family in premalignant and malignant tumours of the 
colorectum. Br J Cancer 49: 681-688, 1984. 
7. Field JK, Yagnisis M, Spandidos DA, Gosney JR, Papadimitriou K, 
Vaughan ED and Stell PM: Low levels of ras p21 oncogene 
expression correlates with clinical outcome in head and neck 
squamous cell carcinoma. Eur J Surg Oncol 18: 168-176, 1992. 
8. Kiaris H, Spandidos DA, Jones AS, Vaughan ED and Field JK: 
Mutations, expression and genomic instability of the H-ras 
proto-oncogene in squamous cell carcinomas of the head and 
neck. Br J Cancer (In press). 
9. Spandidos DA, Lamothe A and Field JK: Clinical relevance of 
oncogene expression in head and neck tumours. Anticancer Res 
5:221-224, 1985. 
10. Leon J, Guerrero I and Pellicer A: Differential expression of the 
ras gene family in mice. Mol Cel Biol 7: 1535-1540, 1987. 
11. Bremmer R and Balmain A: Genetic changes in skin tumour 
progression: correlation between presence of a mutant ras gene 
and loss of heterozygosity on mouse chromosome 7. Cell 61: 
407-417, 1990. 
12. Neubauer A, Neubauer Β, He M, Eifert Ρ, Iglehart D, Frye RA 
and Liu E: Analysis of gene amplification in archival tissue by 
differential polymerase chain reaction. Oncogene 7: 1019-1025, 
1992. 
13. Sheng ZM, Barrois M, Klijanienko J, Micheau C, Richard JM 
and Riou G: Analysis of the c-Ha-ras-1 gene for deletion, 
mutation, amplification and expression in lymph node 
metastasis of human head and neck carcinomas. Br J Cancer 62: 
398-404, 1990. 
14. Kotsinas A, Kiaris Η and Spandidos DA: A method to detect 
and quantitate the expression of normal versus mutant H-ras 
transcripts at codon 12. Int J Oncol 5: 479-483, 1994. 
15. Duesberg PH: Oncogenes and cancer. Science 267: 1407-1408, 
1995. 
16. Chakraborty AK, Cichutec Κ and Duesberg PH: Transforming 
function of proto-rai genes depends on heterologous promoters 
and is enhanced by specific point mutations. Proc Natl Acad Sci 
USA 88: 2217-2221, 1991. 
17. Lang M, Treinies I, Duesberg PH, Kurth R and Cichutek K: 
Development of transforming function during transduction of 
proto-rai genes into Harvey sarcoma virus. Proc Natl Acad Sci 
USA 91: 654-658, 1994. 
18. Scambia G, Catozzi L, Panici PB, Ferrandina G, Almadori G, 
Paludetti G, Cadoni G, Distegano M, Mancuso S and Maurizi M: 
Expression of ras oncogene p21 protein in normal and neo­
plastic laryngeal tissues: correlation with histopathological 
features and epidermal growth factor receptors. Br J Cancer 69: 
995-999, 1994. 
19. Field JK: Oncogenes and tumour suppressor genes in squamous 
cell carcinomas of the head and neck. Eur J Cancer Oral Oncol 
28B: 67-76, 1992. 
20. Kotsinas A, Spandidos DA, Romanowski Ρ and Wyllie A: 
Relative expression of wild type and activated Ki-ras 2 onco­
gene in colorectal carcinomas. Int J Oncol 3: 841-845, 1993. 
21. Schwab M, Varmus HE and Bishop JM: Human N-mvc gene 
contributes to neoplastic transformation of mammalian cells in 
culture. Nature 316: 160-162, 1984. 
22. Kiaris H, Spandidos DA, Jones AS and Field JK: Loss of 
heterozygosity and microsatellite instability of the H-ras gene in 
cancer of the head and neck. Int J Oncol 5: 579-582, 1994. 
23. Lee WF Schwab M, Westaway D and Varmus HE: Augmented 
expression of normal c-myc is sufficient for co-transformation 
of rat embryo cells with a mutant ras gene. Mol Cel Biol 5: 
3345-3356, 1985. 
24. Tamanoi F: Inhibitors of Ras farnesyltransferases. TIBS 18: 
349-353, 1993. 
